In the BC tumor microenvironment, TEX significantly impacts immune escape and therapeutic response, with immune regulation central to TEX through inhibitory receptors (e.g., PD-1), cytokines (e.g., IL-10), and immunoregulatory cells like TAMs. This evidence concerns the gene IL10 and breast cancer.